Home LiteratureArticle Details
PMID: 19102781 Published · epublish English

Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication.

Retrovirology ·Vol. 5 ·2009-03-03

Ahluwalia Jasmine K, Khan Sohrab Zafar, Soni Kartik, Rawat Pratima, Gupta Ankit, Hariharan Manoj, Scaria Vinod, Lalwani Mukesh, Pillai Beena, Mitra Debashis, Brahmachari Samir K

Abstract

Cellular miRNAs play an important role in the regulation of gene expression in eukaryotes. Recently, miRNAs have also been shown to be able to target and inhibit viral gene expression. Computational predictions revealed earlier that the HIV-1 genome includes regions that may be potentially targeted by human miRNAs. Here we report the functionality of predicted miR-29a target site in the HIV-1 nef gene.,We find that the human miRNAs hsa-miR-29a and 29b are expressed in human peripheral blood mononuclear cells. Expression of a luciferase reporter bearing the nef miR-29a target site was decreased compared to the luciferase construct without the target site. Locked nucleic acid modified anti-miRNAs targeted against hsa-miR-29a and 29b specifically reversed the inhibitory effect mediated by cellular miRNAs on the target site. Ectopic expression of the miRNA results in repression of the target Nef protein and reduction of virus levels.,Our results show that the cellular miRNA hsa-miR29a downregulates the expression of Nef protein and interferes with HIV-1 replication.

Article Info
Journal
Retrovirology
Abbr.
Retrovirology
Published
2009-03-03
Indexed
2009-02-04
Updated
2014-09-01
Language
English
Country/Region
England
NLM ID
101216893
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]